The invention discloses a profile matching and communication technology on the top of Mobile Ad-hoc Networking. The invention allows to share users interests and profile in the nearby region to connect similar users to chat and share files.
Researchers at UC San Diego have developed a new cell therapy delivery platform which offers a number of advantages over the current state of the art for this type of clinically important procedure. Utilizing this platform renders therapeutic cells undeniably safe, even after virus integration, extensive genetic engineering, and/or genome editing. It also provides a robust vehicle to deliver a wide range of clinically important therapeutic products, such as genetically engineered-enhanced cytokines, plasmids, gene therapy constructs, oncolytic viruses, small therapeutic RNAs, and peptides.
MGMT is a DNA repair protein that interferes with the cytotoxic action of alkylating chemotherapy agents. Because of the prevalence of this protein in tumors, especially brain tumors, there is a great need for the discovery of an inhibitor that will not harm bone marrow stem cells. This invention has solved this problem through the discovery of a novel use for an existing FDA approved drug used for the treatment of alcoholism, disulfiram.
Reference Number: D-1000
Features, Benefits, and Advantages:
The alcohol aversion drug disulfiram (DSF) reacts and conjugates with the protein-bound nucleophilic cysteines and is known to elicit anticancer effects alone or improve the efficacy of many cancer drugs. This invention investigated the effects of disulfiram on human MGMT, a DNA repair protein and chemotherapy target that removes the mutagenic O6-akyl groups from guanines, and thus confers resistance to alkylating agents in brain tumors. Treatment with DSF inhibited the MGMT activity in two brain tumor cell lines in a rapid and dose-dependent manner. DSF was a weaker inhibitor of MGMT, compared to the established O6-benzylguanine, nevertheless, the 24-36 h suppression of MGMT activity in cell cultures vastly increased the alkylation-induced DNA interstrand crosslinking, G2/M cell cycle blockade, cytotoxicity, and the levels of apoptotic markers.
A U.S. national stage patent application 15/116,757 was filed on 08/04/2016.
This technology has been produced and tested.
Kalkunte Srivenugopal, Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, Texas
Ameya Paranjpe, Ruiwen Zhang, Francis Ali-Osman, George C. Bobustuc, and Kalkunte S. Srivenugopal
Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage, Carcinogenesis 2014 35: 692-702
pediatric brain cancer, disulfiram, MGMT inhibitors, guinines, chemotherapy
This technology introduces a highly sensitive microbial
diagnostic platform to screen and detect microbial organisms in an infectious sample
and identify each pathogen along with the pathogen concentration using a
combination of probes and compressive sensing mathematical algorithms
Professor Nakano and coworkers have discovered an in utero treatment to prevent CHD. A chemical screen revealed that high maternal glucose levels interfered with development of heart muscle cellsviaa key regulatory pathway. By inhibiting this pathway using the FDA-approved small molecule, CHD could be prevented in mouse models. This chemical has been shown to cross the placental barrier and is non-toxic and efficacious at the dose used in this method.
Researchers led by Professor Yang Yang have developed a novel strategy to decrease heterogeneity in perovskite thin films by adding novel Lewis bases. The additives have been shown to improve microscale properties by enhancing crystallinity and decreasing grain boundaries and related defects. The bases can be easily added to the solution before further processing and do not need to be removed after crystal growth. Perovskite devices using this method demonstrated a 10% increase in PCE and the best performing device achieved a PCE of 18.6%.
Researchers at UCLA in the Department of Radiology have developed a cheaper and safer way to measure coronary calcium levels, a predictor of heart disease. Their invention combines a 3-D image of the heart, generated via tomosynthesis, along with a unique algorithm to detect coronary calcium deposits. This technology has the capability to detect moderate calcium deposits in the coronary arteries. The advantages this invention has over CT scans include cheaper costs and decreased exposure to radiation. This innovation carries a tenth of the cost to build compared to CT scanners. The radiation exposure from this new technology can be 10-200 times less than CT scanners.
Inventors at UCLA have developed a bi-pedal robot that incorporates multiple airtight bladders containing a gas that is lighter than air, such as helium, to provide support and balance. The suspended body of the robot maintains a neutral level in the air due to balloons. When the body is pulled to a different level due to bi-pedal motion, the body naturally returns the neutral level, and reduces the likelihood of the robot tipping or falling. This robot requires only extremely small actuators and no sensors. Locomotion can be achieved by a number of mechanisms, such as actuators or an external air vortex. As it moves, the robot’s body will maintain equilibrium without additional effort due to the buoyancy of the gas-filled balloons.
See video: https://www.youtube.com/watch?v=EdSoUbXirVI